Compare · MTD vs QTRX
MTD vs QTRX
Side-by-side comparison of Mettler-Toledo International Inc. (MTD) and Quanterix Corporation (QTRX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both MTD and QTRX operate in Biotechnology: Laboratory Analytical Instruments (Industrials), so they compete in similar markets.
- MTD is the larger of the two at $32.84B, about 226.2x QTRX ($145.2M).
- Over the past year, MTD is up 20.3% and QTRX is down 50.9% - MTD leads by 71.2 points.
- QTRX has been more active in the news (6 items in the past 4 weeks vs 2 for MTD).
- MTD has more recent analyst coverage (25 ratings vs 13 for QTRX).
- Company
- Mettler-Toledo International Inc.
- Quanterix Corporation
- Price
- $1621.41-1.12%
- $2.87-6.37%
- Market cap
- $32.84B
- $145.2M
- 1M return
- +14.81%
- -7.73%
- 1Y return
- +20.28%
- -50.94%
- Industry
- Biotechnology: Laboratory Analytical Instruments
- Biotechnology: Laboratory Analytical Instruments
- Exchange
- NYSE
- NASDAQ
- IPO
- 1997
- 2017
- News (4w)
- 2
- 6
- Recent ratings
- 25
- 13
Mettler-Toledo International Inc.
Mettler-Toledo International Inc. manufactures and supplies precision instruments and services worldwide. It operates in five segments: U.S. Operations, Swiss Operations, Western European Operations, Chinese Operations, and Other. The company offers weighing instruments for laboratory, industrial, packaging, logistics, and food retailing applications; various related analytical instruments and automated chemistry solutions used in drug and chemical compound discovery and development; metal detection and other end-of-line product inspection systems used in production and packaging for food processing and packaging, pharmaceutical, packaged consumer goods, and other industries; and solutions that are used in various process analytics applications. Its laboratory instruments include laboratory balances, liquid pipetting solutions, automated laboratory reactors, titrators, pH meters, process analytics sensors and analyzer technologies, physical value analyzers, thermal analysis systems, and other analytical instruments; and LabX, a laboratory software platform. The company's industrial instruments comprise industrial weighing instruments and related terminals, automatic dimensional measurement and data capture solutions, vehicle scale systems, industrial software, and product inspection systems. Its retail weighing solutions consist of networked scales and software, and stand-alone scales for handling fresh goods, such as meats, vegetables, fruits, and cheeses. The company serves the life science industry, and independent research organizations; food and beverage producers; food retailers; chemical, specialty chemical, and cosmetics companies; food retailers; transportation and logistics, metals, and electronics industries; and the academic community. It markets its products through its direct sales force and indirect distribution channels. The company was incorporated in 1991 and is based in Columbus, Ohio.
Quanterix Corporation
Quanterix Corporation, a life sciences company, develops and markets digital immunoassay platforms that advances precision health for life sciences research and diagnostics in North America, Europe, the Middle East, Africa, and the Asia Pacific regions. The company offers HD-X instrument, a sensitive automated multiplex protein detection platform; and SR-X instrument that enables researchers to apply Simoa detection technology in various applications, including direct detection of nucleic acids. It also provides SP-X instrument that is based on Simoa planar array technology for the measurement of multiplex chemiluminescent immunoassays. The company's products include assay kits and other consumables such as reagents. In addition, it offers contract research services, including sample testing, homebrew assay development, and custom development services. The company primarily operates in the areas of neurology, oncology, cardiology, infectious diseases, and inflammation. It sells its products for the life science research sector primarily to laboratories associated with academic and governmental research institutions, as well as pharmaceutical, biotechnology, and contract research companies through a direct sales force, support organizations, and distributors or sales agents. The company was formerly known as Digital Genomics, Inc. and changed its name to Quanterix Corporation in August 2007. Quanterix Corporation was incorporated in 2007 and is headquartered in Billerica, Massachusetts.
Latest MTD
- Mettler-Toledo International Inc. to Host Investor Meeting
- Mettler-Toledo International Inc. to Host Third Quarter 2026 Earnings Conference Call
- UBS resumed coverage on Mettler-Toledo with a new price target
- Rothschild & Co Redburn initiated coverage on Mettler-Toledo with a new price target
- Director Shuman-Fabbri Natalia was granted 16 shares (SEC Form 4)
- RBC Capital Mkts initiated coverage on Mettler-Toledo with a new price target
- President and CEO Kaltenbach Patrick exercised 942 shares at a strike of $1,024.55 and sold $1,342,350 worth of shares (942 units at $1,425.00) (SEC Form 4)
- Director Salice Thomas P exercised 417 shares at a strike of $397.95 and sold $600,651 worth of shares (417 units at $1,440.41) (SEC Form 4)
- Director Salice Thomas P exercised 415 shares at a strike of $397.95 and sold $599,517 worth of shares (415 units at $1,444.62) (SEC Form 4)
- Head of Process Analytics Keller Gerry exercised 240 shares at a strike of $720.81 and sold $342,514 worth of shares (240 units at $1,427.14) (SEC Form 4)
Latest QTRX
- SEC Form 4 filed by Quanterix Corporation
- Quanterix and Innovita Expand IVD Access in China with National Medical Products Administration Approvals
- Director Magovcevic-Liebisch Ivana converted options into 4,224 shares, increasing direct ownership by 36% to 15,883 units (SEC Form 4)
- Director Mendel Scott was granted 4,398 shares, increasing direct ownership by 18% to 28,454 units (SEC Form 4)
- Director Donnelly William P was granted 6,964 shares, increasing direct ownership by 4% to 169,365 units (SEC Form 4)
- Quanterix Delivers on Spatial Biology Content Innovation Commitments at ESSB 2026
- SEC Form 4 filed by Chief Commercial Officer Gute James Edward Jr.
- Quanterix Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Chief Technology Officer Miller Michael Francis converted options into 1,558 shares and covered exercise/tax liability with 467 shares, increasing direct ownership by 3% to 38,452 units (SEC Form 4)
- Quanterix Names Dr. Yuri Fesko Chief Medical Officer